Arch Therapeutics and MIT sign licensing agreement

The license provides Arch Therapeutics exclusive and non-exclusive commercialization rights to a range of patents and applications for technology that includes a family of compositions to control bleeding and the movement of other bodily substances.

Arch Therapeutics’s compositions are clear, water-like, non-sticky materials that can be easily squirted through a syringe onto a bleeding wound. The company expects the compositions to improve results in both surgical and trauma settings. Unlike existing materials that are difficult to prepare, toxic, or inhibit healing, based on animal testing to date, Arch Therapeutics’s novel synthetic products appear to be safe, easy to prepare and easy to use.

Rutledge Ellis-Behnke, research scientist in the MIT Department of Brain and Cognitive Sciences and a founder of Arch Therapeutics, said: “Despite advances in patient care, the arsenal of tools that doctors use to stop bleeding still has its limitations. With our compositions, we expect to more efficiently control bleeding in surgical and trauma settings.”